Prelude Therapeutics’ lead asset won’t be making it to the second act. | Prelude Therapeutics’ lead asset won’t be making it ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Vedanta Biosciences’ dreams of using live bacteria to treat inflammatory bowel disease (IBD) have been dashed. | Vedanta ...

Clinical trial tech outfit Medidata has elevated a new strategy leader from within. | Clinical trial tech outfit Medidata has elevated a new strategy leader from within. Industry veteran Lisa ...

Conformal Medical has raised $32 million to support the development of its heart implant designed to reduce the lifetime risk ...

As for recent success stories from its biotech portfolio, Hatteras namechecked Kymera Therapeutics. The VC fund contributed ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting ...

Generation Bio is shedding 90% of its workforce after the biotech acknowledged it’s unlikely to find the cash to take its ...